D. Ricard, A. Idbaih, F. Ducray, M. Lahutte, K. Hoang-xuan et al., Primary brain tumours in adults, The Lancet, vol.379, issue.9830, pp.1984-96, 2012.
DOI : 10.1016/S0140-6736(11)61346-9

R. Stupp, M. Hegi, W. Mason, M. Van-den-bent, M. Taphoorn et al., Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, The Lancet Oncology, vol.10, issue.5, pp.459-66, 2009.
DOI : 10.1016/S1470-2045(09)70025-7

J. Buckner, P. Brown, O. Neill, B. Meyer, F. Wetmore et al., Central Nervous System Tumors, Mayo Clinic Proceedings, vol.82, issue.10, pp.1271-86, 2007.
DOI : 10.4065/82.10.1271

S. Bao, Q. Wu, R. Mclendon, Y. Hao, Q. Shi et al., Glioma stem cells promote radioresistance by preferential activation of the DNA damage response, Nature, vol.8, issue.7120, pp.756-60, 2006.
DOI : 10.1038/nature05236

S. Singh, I. Clarke, M. Terasaki, V. Bonn, C. Hawkins et al., Identification of a cancer stem cell in human brain tumors, Cancer Res, vol.63, issue.18, pp.5821-814522905, 2003.

S. Singh, C. Hawkins, I. Clarke, J. Squire, J. Bayani et al., Identification of human brain tumour initiating cells, Nature, vol.64, issue.7015, pp.396-401, 2004.
DOI : 10.1038/nature03128

X. Yuan, J. Curtin, Y. Xiong, G. Liu, S. Waschsmann-hogiu et al., Isolation of cancer stem cells from adult glioblastoma multiforme, Oncogene, vol.23, issue.58, pp.9392-9400, 2004.
DOI : 10.1038/sj.onc.1208311

E. Vauleon, T. Avril, B. Collet, J. Mosser, and V. Quillien, Overview of cellular immunotherapy for 18 patients with glioblastoma, Clin. Dev. Immunol. Article ID, vol.2010, issue.18, p.689171, 2010.

K. Chow and S. Gottschalk, Cellular immunotherapy for high-grade glioma, Immunotherapy, vol.3, issue.3, pp.423-457, 2011.
DOI : 10.2217/imt.10.110

V. Dutoit, C. Herold-mende, N. Hilf, O. Schoor, P. Beckhove et al., Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy, Brain, vol.135, issue.4, pp.1042-54, 2012.
DOI : 10.1093/brain/aws042

D. Gerber and J. Laterra, Emerging monoclonal antibody therapies for malignant gliomas, Expert Opinion on Investigational Drugs, vol.5, issue.4, pp.477-94, 2007.
DOI : 10.1097/00006123-199711000-00005

D. Chung, H. Shin, and Y. Hong, A New Hope in Immunotherapy for Malignant Gliomas: Adoptive T Cell Transfer Therapy, Journal of Immunology Research, vol.164, issue.7, p.326545, 2014.
DOI : 10.1038/nm1100

M. Lefranc and T. Rabbitts, A nomenclature to fit the organization of the human T-cell receptor ?? and ?? genes, Research in Immunology, vol.141, issue.6, pp.615-80923, 1990.
DOI : 10.1016/0923-2494(90)90068-A

B. Silva-santos, K. Serre, and H. Norell, ???? T cells in cancer, Nature Reviews Immunology, vol.45, issue.11, pp.683-91, 2015.
DOI : 10.1038/nri3904

M. Bonneville and E. Scotet, Human V??9V??2 T cells: promising new leads for immunotherapy of infections and tumors, Current Opinion in Immunology, vol.18, issue.5, pp.539-585, 2006.
DOI : 10.1016/j.coi.2006.07.002

D. Yeh, D. Chen, T. Chao, S. Chen, H. Wang et al., EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid, In vivo, vol.28, issue.5, pp.1001-425189922, 2014.

J. Fournie, H. Sicard, M. Poupot, C. Bezombes, A. Blanc et al., What lessons can be learned from ???? T cell-based cancer immunotherapy trials?, Cellular and Molecular Immunology, vol.8, issue.1, pp.35-41, 2013.
DOI : 10.1038/cmi.2012.39

T. Santolaria, M. Robard, A. Leger, V. Catros, M. Bonneville et al., Repeated systemic administrations of both aminobisphosphonates and human Vgamma9Vdelta2 T cells efficiently control tumor development in vivo, J. Immunol, vol.191, issue.4, 1993.

T. Nakazawa, M. Nakamura, Y. Park, Y. Motoyama, Y. Hironaka et al., Cytotoxic human peripheral blood-derived ????T cells kill glioblastoma cell lines: implications for cell-based immunotherapy for patients with glioblastoma, Journal of Neuro-Oncology, vol.5, issue.1, pp.31-924062140, 2014.
DOI : 10.1007/s11060-013-1258-4

E. Cimini, P. Piacentini, A. Sacchi, C. Gioia, S. Leone et al., Zoledronic Acid Enhances V??2 T-Lymphocyte Antitumor Response to Human Glioma Cell Lines, International Journal of Immunopathology and Pharmacology, vol.20, issue.1, pp.139-4821496396, 2011.
DOI : 10.1177/039463201102400116

A. Das, J. James, X. Zhao, J. Rahnenfuhrer, and I. Ahmad, Identification of c-Kit receptor as a regulator of adult neural stem cells in the mammalian eye: interactions with Notch signaling, Developmental Biology, vol.273, issue.1, pp.87-105, 2004.
DOI : 10.1016/j.ydbio.2004.05.023

S. Donnou, S. Fisson, D. Mahe, A. Montoni, and D. Couez, Identification of new CNS-resident macrophage subpopulation molecular markers for the discrimination with murine systemic macrophages, Journal of Neuroimmunology, vol.169, issue.1-2, pp.39-49, 2005.
DOI : 10.1016/j.jneuroim.2005.07.016

C. Harly, Y. Guillaume, S. Nedellec, C. Peign-e, H. M?-onkk?-onen et al., Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human ???? T-cell subset, Blood, vol.120, issue.11, pp.2269-79, 2012.
DOI : 10.1182/blood-2012-05-430470

E. Brocard, K. Oizel, L. Lalier, C. Pecqueur, F. Paris et al., Radiation-induced PGE2 sustains human glioma cells growth and survival through EGF signaling, Oncotarget, vol.6, issue.9, pp.6840-6849, 2015.
DOI : 10.18632/oncotarget.3160

D. Cho, S. Lin, W. Yang, H. Lee, D. Hsu et al., Targeting Cancer Stem Cells for Treatment of Glioblastoma Multiforme, Cell Transplantation, vol.22, issue.4, pp.731-740, 2013.
DOI : 10.3727/096368912X655136

N. Thon, K. Damianoff, J. Hegermann, S. Grau, B. Krebs et al., Presence of pluripotent CD133+ cells correlates with malignancy of gliomas, Molecular and Cellular Neuroscience, vol.43, issue.1, pp.51-60, 2010.
DOI : 10.1016/j.mcn.2008.07.022

D. Silver, F. Siebzehnrubl, M. Schildts, A. Yachnis, G. Smith et al., Chondroitin Sulfate Proteoglycans Potently Inhibit Invasion and Serve as a Central Organizer of the Brain Tumor Microenvironment, Journal of Neuroscience, vol.33, issue.39, pp.15603-173004, 2013.
DOI : 10.1523/JNEUROSCI.3004-12.2013

C. Morita, C. Jin, G. Sarikonda, and H. Wang, Nonpeptide antigens, presentation mechanisms, and immunological memory of human V??2V??2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens, Immunological Reviews, vol.151, issue.16, pp.59-76, 2007.
DOI : 10.1002/eji.1830220506

A. Sandstrom, C. Peigne, A. Leger, J. Crooks, F. Konczak et al., The Intracellular B30.2 Domain of Butyrophilin 3A1 Binds Phosphoantigens to Mediate Activation of Human V??9V??2??T Cells, Immunity, vol.40, issue.4, pp.490-500, 2014.
DOI : 10.1016/j.immuni.2014.03.003

L. Pereboeva, L. Harkins, S. Wong, and L. Lamb, The safety of allogeneic innate lymphocyte therapy for glioma patients with prior cranial irradiation, Cancer Immunology, Immunotherapy, vol.176, issue.5, pp.551-62, 2015.
DOI : 10.1007/s00262-015-1662-z

L. Lamb, J. Musk, P. Ye, Z. Van-rhee, F. Geier et al., Human ????+ T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response, Bone Marrow Transplantation, vol.27, issue.6, pp.601-607, 2001.
DOI : 10.1038/sj.bmt.1702830

S. Bailey, P. Carpentier, E. Mcmahon, W. Begolka, and S. Miller, Innate and Adaptive Immune Responses of the Central Nervous System, Critical Reviews??? in Immunology, vol.26, issue.2, pp.149-88, 2006.
DOI : 10.1615/CritRevImmunol.v26.i2.40

A. Louveau, I. Smirnov, T. Keyes, J. Eccles, S. Rouhani et al., Structural and functional features of central nervous system lymphatic vessels, Nature, vol.14, issue.7560, pp.337-378, 2015.
DOI : 10.1038/nature14432

G. Jung, M. Brandl, W. Eisner, P. Fraunberger, G. Reifenberger et al., Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: Evidence for in situ T???cell activation and therapeutic efficacy, 9999%3c::AID-IJC1038%3e3.3.CO, pp.225-255, 2001.
DOI : 10.1002/1097-0215(200002)9999:9999<::AID-IJC1038>3.3.CO;2-7

K. Quattrocchi, C. Miller, S. Cush, S. Bernard, S. Dull et al., Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas, Journal of Neuro-Oncology, vol.45, issue.2, pp.141-5710778730, 1999.
DOI : 10.1023/A:1006293606710

A. Sloan, R. Dansey, L. Zamorano, G. Barger, C. Hamm et al., Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony???stimulating factor and adoptive transfer of anti-CD3???activated lymphocytes, Neurosurgical Focus, vol.9, issue.6, 2000.
DOI : 10.3171/foc.2000.9.6.10

M. Westphal, S. Yla-herttuala, J. Martin, P. Warnke, P. Menei et al., Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial, The Lancet Oncology, vol.14, issue.9, pp.823-856, 2013.
DOI : 10.1016/S1470-2045(13)70274-2

M. Rogers, J. Crockett, F. Coxon, and J. Monkkonen, Biochemical and molecular mechanisms of action of bisphosphonates, Bone, vol.49, issue.1, pp.34-41, 2011.
DOI : 10.1016/j.bone.2010.11.008

H. Kobayashi, Y. Tanaka, J. Yagi, N. Minato, and K. Tanabe, Phase I/II study of adoptive transfer of ???? T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma, Cancer Immunology, Immunotherapy, vol.30, issue.Suppl 1, pp.1075-84, 2011.
DOI : 10.1007/s00262-011-1021-7

R. Coleman, Risks and benefits of bisphosphonates, British Journal of Cancer, vol.2, issue.11, pp.1736-1776, 2008.
DOI : 10.1093/jnci/djm025

H. Weiss, U. Pfaar, A. Schweitzer, H. Wiegand, A. Skerjanec et al., Biodistribution and Plasma Protein Binding of Zoledronic Acid, Drug Metabolism and Disposition, vol.36, issue.10, pp.2043-918625688, 2008.
DOI : 10.1124/dmd.108.021071

Y. Kato, Y. Tanaka, H. Tanaka, S. Yamashita, and N. Minato, Requirement of Species-Specific Interactions for the Activation of Human ???? T Cells by Pamidronate, The Journal of Immunology, vol.170, issue.7, pp.3608-3621, 2003.
DOI : 10.4049/jimmunol.170.7.3608

R. Sabatino, A. Antonelli, S. Battistelli, R. Schwendener, M. Magnani et al., Macrophage depletion by free bisphosphonates and zoledronate-loaded red blood cells):e101260; PMID:24968029, PloS One, vol.9, issue.6, 2014.

E. Rietkotter, K. Menck, A. Bleckmann, K. Farhat, M. Schaffrinski et al., Zoledronic acid inhibits macrophage/microglia-assisted breast cancer cell invasion, Oncotarget, vol.4, issue.9, pp.1449-60, 2013.
DOI : 10.18632/oncotarget.1201